Solid Q1, but with adj. EBIT 3% below due to net recruitments. Fine-tuned sales, but '24e-'26e EBIT down 4-3% on higher opex. Share to benefit from improved organic growth: up to BUY (Hold).
Q1 likely marked the negative organic growth trough. But visibility remains low and valuation still elevated. EBIT +1-5% mainly on FX, we stick to HOLD, TP SEK 350 (330).
Cost control in DM behind Q1 beat, adj. EBITA up 4%. We estimate 55% adj. EBITA growth in Q2e vs. 25% in Q1. M&A outlook positive, BUY on quality growth, TP SEK 135 (130).